Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:45:49.705Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:45:49.705Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3f32b4356dd318fc5fc0a902c875af90b1a094ceb52f500a6b854293a5898a5a
FORWARD PE RATIO
N/A
Basel Medical Group Ltd Ordinary Shares
Market Cap
$5.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $5.21M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
Consensus estimates for this stock are reported in SGD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
